This company has been marked as potentially delisted and may not be actively trading. Nightstar Therapeutics (NITE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NITE vs. PRME, IKT, PLX, ZIVO, IZTC, CVM, CRTX, JATT, FNCH, and CLDIShould you be buying Nightstar Therapeutics stock or one of its competitors? The main competitors of Nightstar Therapeutics include Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), CEL-SCI (CVM), Cortexyme (CRTX), JATT Acquisition (JATT), Finch Therapeutics Group (FNCH), and Calidi Biotherapeutics (CLDI). These companies are all part of the "medical" sector. Nightstar Therapeutics vs. Its Competitors Prime Medicine Inhibikase Therapeutics Protalix BioTherapeutics ZIVO Bioscience Invizyne Technologies CEL-SCI Cortexyme JATT Acquisition Finch Therapeutics Group Calidi Biotherapeutics Nightstar Therapeutics (NASDAQ:NITE) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Do analysts prefer NITE or PRME? Prime Medicine has a consensus price target of $8.92, indicating a potential upside of 176.49%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Nightstar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nightstar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Is NITE or PRME more profitable? Nightstar Therapeutics' return on equity of -30.89% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Nightstar TherapeuticsN/A -30.89% -27.65% Prime Medicine N/A -107.87%-74.97% Which has more volatility and risk, NITE or PRME? Nightstar Therapeutics has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500. Do institutionals and insiders have more ownership in NITE or PRME? 32.8% of Nightstar Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, NITE or PRME? Nightstar Therapeutics has higher earnings, but lower revenue than Prime Medicine. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNightstar TherapeuticsN/AN/A-$36.86M-$1.26-25.45Prime Medicine$4.96M87.48-$198.13M-$1.56-2.07 Does the media favor NITE or PRME? In the previous week, Prime Medicine had 10 more articles in the media than Nightstar Therapeutics. MarketBeat recorded 10 mentions for Prime Medicine and 0 mentions for Nightstar Therapeutics. Prime Medicine's average media sentiment score of 0.27 beat Nightstar Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Overall Sentiment Nightstar Therapeutics Neutral Prime Medicine Neutral SummaryPrime Medicine beats Nightstar Therapeutics on 10 of the 15 factors compared between the two stocks. Get Nightstar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NITE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NITE vs. The Competition Export to ExcelMetricNightstar TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.08B$279.74M$5.74B$9.56BDividend YieldN/AN/A4.53%4.07%P/E Ratio-25.45N/A30.4325.14Price / SalesN/A538.67392.4187.63Price / CashN/A22.4437.0358.50Price / Book5.4410.148.956.21Net Income-$36.86M-$115.81M$3.26B$265.38M Nightstar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NITENightstar TherapeuticsN/A$32.07-0.8%N/A+33.1%$1.08BN/A-25.4547PRMEPrime Medicine2.8561 of 5 stars$3.70+6.8%$8.92+141.3%-25.9%$496.96M$4.96M-1.80234Gap DownIKTInhibikase Therapeutics2.0637 of 5 stars$1.75-0.3%$6.50+272.5%+19.1%$129.73MN/A-0.656News CoveragePLXProtalix BioTherapeutics3.0584 of 5 stars$1.63-0.9%$15.00+823.1%+65.1%$129.36M$59.76M-12.50200News CoverageAnalyst RevisionGap DownZIVOZIVO Bioscience0.2751 of 5 stars$18.07+0.3%N/A+109.8%$68.99M$15.85K-3.7010News CoverageGap DownIZTCInvizyne TechnologiesN/A$9.84-1.7%N/AN/A$61.52MN/A0.0029News CoverageGap DownCVMCEL-SCI1.5991 of 5 stars$7.44-2.5%N/A-73.5%$51.20MN/A-15.5043CRTXCortexymeN/A$1.60-3.0%N/A+163.9%$48.24MN/A-0.5455News CoverageJATTJATT AcquisitionN/A$1.41-0.7%N/A-50.3%$24.32MN/A0.003High Trading VolumeFNCHFinch Therapeutics GroupN/A$12.25+0.1%N/A+8.2%$19.67MN/A-1.39190CLDICalidi Biotherapeutics0.7987 of 5 stars$5.46+3.2%N/A-90.7%$16.52MN/A0.0038News Coverage Related Companies and Tools Related Companies PRME Alternatives IKT Alternatives PLX Alternatives ZIVO Alternatives IZTC Alternatives CVM Alternatives CRTX Alternatives JATT Alternatives FNCH Alternatives CLDI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NITE) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Nightstar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access